Global Artificial Intelligence (AI) In Drug Discovery Market Report 2026–2035: Key Forecasts and Growth Areas
Uncover key drivers, emerging technologies, and competitive movements shaping the artificial intelligence (ai) in drug discovery market from 2026–2035 with trusted insights from The Business Research Company
How is the Artificial Intelligence (AI) In Drug Discovery Market size predicted to change over the forecast window of 2026–2035?
The artificial intelligence (AI) in drug discovery market size has seen substantial growth in recent years. It is anticipated to increase from $2.33 billion in 2025 to $2.93 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 25.9%. This past growth can be attributed to factors such as higher pharmaceutical R&D expenditure, the increasing complexity of drug discovery pipelines, the expanding availability of biological and chemical datasets, the initial adoption of machine learning in bioinformatics, and more collaborations between pharmaceutical and technology firms.
The market for artificial intelligence (AI) in drug discovery is poised for significant expansion over the coming years. This market is projected to reach $7.42 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 26.2%. Factors contributing to this anticipated growth include the increasing integration of generative AI models, a surging need for precision therapeutics, the broadening scope of AI-enabled clinical trial design, increasing capital directed towards cloud-based discovery platforms, and the regulatory embrace of AI-supported drug development. Key trends anticipated during this period encompass the escalating utilization of AI for target identification, a rise in deep learning applications for molecule screening, the expanding incorporation of virtual drug screening platforms, the proliferation of AI-powered lead optimization instruments, and a heightened emphasis on expediting drug development schedules.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3411&type=smp
Which Drivers Are Contributing To The Expansion Of The Artificial Intelligence (AI) In Drug Discovery Market?
The increasing need for personalized medicine is projected to fuel the expansion of artificial intelligence (AI) within the drug discovery market in the future. Personalized medicine involves a focused method for preventing, diagnosing, and treating diseases, utilizing an individual’s genetic, proteomic, or biological makeup to inform clinical choices. Its growing adoption stems from the escalating requirement for accurate, tailored therapies that enhance treatment outcomes and mitigate negative side effects. AI facilitates this transition by speeding up the discovery of molecular targets, refining potential drug candidates, and strengthening clinical decision-making across the entire development process. For example, data from February 2024 by the Personalized Medicine Coalition, a US-based advocacy and research group, indicated that the U.S. FDA sanctioned 26 new personalized treatments in 2023, comprising 20 new molecular entities and 6 gene- or cell-based therapies. Consequently, the expanding demand for personalized medicine is a key impetus for the advancement of artificial intelligence (AI) in the drug discovery market.
What Segment Categories Are Covered In The Artificial Intelligence (AI) In Drug Discovery Market?
The artificial intelligence (AI) in drug discovery market covered in this report is segmented –
1) By Technology: Context-Aware Processing, Natural Language Processing, Deep Learning
2) By Drug Type: Small Molecules, Large Molecules
3) By Therapeutic Type: Metabolic Disease, Cardiovascular Disease, Oncology, Neurodegenerative Diseases, Anti-Infective Diseases, Respiratory Diseases, Other Therapeutics
4) By End User: Pharmaceutical Companies, Biopharmaceutical Companies, Academic And Research Institutes, Other End-Users
Subsegments:
1) By Context-Aware Processing: Contextual Data Integration, Predictive Modeling, Adaptive Learning Systems
2) By Natural Language Processing (NLP): Text Mining And Analysis, Drug Interaction Extraction, Clinical Trial Data Analysis
3) By Deep Learning: Neural Networks, Convolutional Neural Networks (CNNs), Recurrent Neural Networks (RNNs), Reinforcement Learning Applications
What Trends Are Reshaping The Dynamics Of The Artificial Intelligence (AI) In Drug Discovery Market?
Leading corporations are allocating capital into firms leveraging artificial intelligence (AI) within the drug discovery market to identify and design novel therapies and offer those models to other drug manufacturers. Strategic financial commitments can provide funding for the research and development of new drugs, which is often a costly and time-consuming endeavor. This funding empowers companies to advance their drug discovery programs and bring new treatments to market. For instance, in July 2023, Nvidia, a US-based software company, invested $50 million in Recursion Pharmaceuticals, a US-based biotech company that utilizes artificial intelligence (AI) for drug discovery. This investment will enable Recursion to accelerate the development of its AI foundation models for biology and chemistry by employing Nvidia’s cloud services.
Which Key Players Are Driving Competition In The Artificial Intelligence (AI) In Drug Discovery Market?
Major companies operating in the artificial intelligence (AI) in drug discovery market are Exscientia, Insilico Medicine, Owkin Inc., XtalPi Inc., Standigm Inc., Innoplexus AG, Atomwise, Inc., BenevolentAI, Deep Genomics Inc., NuMedii, Inc., Verge Genomics, Inc., Berg LLC, Cyclica Inc., Iktos, Quris, Adagene Inc., Gero Pte. Ltd., IBM Corporation, Microsoft Corporation, NVIDIA Corporation, Alphabet Inc., DeepMind Technologies Limited, IQVIA Holdings Inc., GNS Healthcare, Inc., GE HealthCare Technologies Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., AbbVie Inc., AstraZeneca PLC, Amgen Inc., GlaxoSmithKline plc, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Ipsen S.A., Galderma S.A.
Access The Complete Report For Deeper Market Insights:
Which Region Is Projected To Lead The Artificial Intelligence (AI) In Drug Discovery Market During The Forecast Period?
North America was the largest region in the artificial intelligence (AI) in drug discovery market in 2025. Western Europe was the second largest region in the global artificial intelligence (AI) in drug discovery market share. The regions covered in the artificial intelligence (AI) in drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Artificial Intelligence (AI) In Drug Discovery Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=3411&type=smp
Browse Through More Reports Similar to the Global Artificial Intelligence (AI) In Drug Discovery Market 2026, By The Business Research Company
Artificial Intelligence Ai In Predictive Toxicology Market Report 2026
Generative Artificial Intelligence Ai In Drug Discovery Market Report 2026
Artificial Intelligence Ai In Biopharmaceuticals Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
